Bionano Genomics, Inc. (BNGO) |
1.97 -0.16 (-7.51%) 10-10 11:56 |
Open: | 2.11 |
High: | 2.12 |
Low: | 1.935 |
Volume: | 410,731 |
Market Cap: | 7(M) |
PE Ratio: | -0.04 |
Exchange: | NASDAQ Capital Market |
Industry: | Medical - Diagnostics & Research |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 5.50 |
Resistance 1: | 3.97 |
Pivot price: | 1.85 |
Support 1: | 1.50 |
Support 2: | 1.25 |
52w High: | 22.8 |
52w Low: | 1.5 |
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
EPS | -43.870 |
Book Value | 11.610 |
PEG Ratio | 0.00 |
Gross Profit | 0.144 |
Profit Margin (%) | -271.02 |
Operating Margin (%) | -115.85 |
Return on Assets (ttm) | -30.9 |
Return on Equity (ttm) | -118.3 |
Wed, 08 Oct 2025
Bionano Genomics announces 1-for-60 reverse stock split - MSN
Tue, 07 Oct 2025
Bionano to Participate in the H.C. Wainwright @ Home Event - The Globe and Mail
Tue, 30 Sep 2025
Bionano’s Unique Genomics Tools Offer Promise—And Plenty Of Risk - Finimize
Sun, 21 Sep 2025
Bionano Genomics Launches $10 Million Public Offering - Yahoo Finance
Wed, 17 Sep 2025
Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering - GlobeNewswire
Tue, 16 Sep 2025
Breakthrough Cancer Detection: Bionano's OGM Technology Shows Promise in Complex Cancer Analysis Studies - Stock Titan
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |